

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims:**

1. (currently amended) A method for treating colon or breast cancer, or combinations thereof, in a patient in need of such treatment, the method comprising administering to the patient a combination of a therapeutically effective amount of *N*-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and a therapeutically effective amount of capecitabine.
2. (previously presented) The method of Claim 1, wherein *N*-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and capecitabine are administered simultaneously.
3. (previously presented) The method of Claim 1, wherein *N*-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide is administered before capecitabine.
4. (previously presented) The method of Claim 1, wherein capecitabine is administered before *N*-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide.

Claims 5-15. (canceled)

16. (previously presented) The method of Claim 1, wherein the cancer is colon cancer.
17. (withdrawn) A pharmaceutical composition comprising capecitabine, *N*-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and a pharmaceutically acceptable carrier.
18. (withdrawn) A kit comprising in one compartment a dosage of *N*-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, and in another compartment a dosage of capecitabine.

19. (withdrawn) The kit of Claim 18 further comprising a blister pack containing separate formulations of a tablet or capsule form of *N*-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and a tablet form of capecitabine.
20. (withdrawn) The kit of Claim 18 comprising instructions for combination administration.